Flexyn

Flexyn (Flexyn) ist ein in Frankreich gemeldetes Nahrungsergänzungsmittel. Status: in Frankreich gemeldet, Inverkehrbringen möglich. 2 Vorschriften zur Verwendung gelten für seine Inhaltsstoffe (Grenzwerte und Warnhinweise).

Marke

Flexyn

Für das Inverkehrbringen verantwortlich

Bralex Webshops B.V.

Status

In Frankreich gemeldet, Inverkehrbringen möglich: Die Verwaltung hat der Meldung nicht widersprochen (weder Zulassung noch Sicherheitsbewertung)

Form

Kapsel

Tagesdosis

2

Gebrauchsanweisung

Übersetzung nicht verfügbar. Originaltext, Sprache: Französisch.

Instructions : Prenez deux gélules par jour. Prenez 1 gélule 30 minutes avant le petit-déjeuner et 1 gélule 30 minutes avant le dîner. Avalez les géluues avec de l’eau.. Conservation : Tenir hors de portée des enfants. Conserver dans un endroit frais et sec, à température ambiante (inférieure à 30 degrés Celsius).

Compl’Alim, Meldungen von Nahrungsergänzungsmitteln · 2026-02-25T07:00:19.740275+01:00

Zielgruppen

Männer und Frauen ab 18 Jahren

Nicht empfohlen (laut Hersteller)

Jugendliche (unter 18 Jahren), Stillende, Nierensteine, Einnahme außerhalb der Mahlzeiten, Schwangere, Niereninsuffizienz, Nierenerkrankung, Herzprobleme, Einnahme von Schilddrüsenmedikamenten, Geschwür (Magen oder Zwölffingerdarm)

Vom Hersteller angegebene Ziele (keine zugelassenen gesundheitsbezogenen Angaben)

Gewichtsmanagement / Abnehmen

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

• Coffea arabica L.
  Warnhinweis, Geltungsbedingung und zitierte Studien lesen

  Offizieller Originaltext auf Englisch.

  GREEN COFFEE BEAN EXTRACT

  Art der Anwendung: Oral

  Vorsichtsmaßnahmen und Warnhinweise

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

  Gegenanzeigen

  Do not use if you are pregnant.

  Monografie von Health Canada vom 31. Oktober 2025

• caféine
  Warnhinweis, Geltungsbedingung und zitierte Studien lesen

  Offizieller Originaltext auf Englisch.

  CAFFEINE

  Art der Anwendung: Oral (Higdon and Frei 2006)

  Vorsichtsmaßnahmen und Warnhinweise

  Gilt für Produkte: providing 100 mg to 400 mg caffeine, per day1.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

  Von Health Canada zitierte Quellen (7)

  • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomisierte Studie
  • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
  • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Übersichtsartikel
  • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Klinische Studie
  • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Metaanalyse
  • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Metaanalyse

  1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

  Gilt für Produkte: providing more than 300 mg caffeine, per day.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

  Von Health Canada zitierte Quellen (1)

  • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Übersichtsartikel

  Gilt für Produkte: providing 400 mg or more caffeine, per day.

  When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

  Von Health Canada zitierte Quellen (8)

  • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
  • Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Fallbericht
  • Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Randomisierte Studie
  • FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
  • Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Randomisierte Studie
  • NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
  • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Fallbericht
  • Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.

  Gegenanzeigen

  Gilt für Produkte: providing more than 400 mg caffeine per day.

  Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

  Von Health Canada zitierte Quellen (7)

  • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomisierte Studie
  • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
  • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Übersichtsartikel
  • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Klinische Studie
  • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Metaanalyse
  • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Metaanalyse

  Bekannte Nebenwirkungen

  Anwendungsbedingung: All products.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

  Von Health Canada zitierte Quellen (2)

  • Hinrichs R, Hunzelmann N, Ritzkowsky A, Zollner TM, Krieg T, Scharffetter-Kochanek K. Caffeine hypersensitivity. Allergy 2002;57(9):859-860. PubMed Fallbericht
  • Infante S, Baeza ML, Calvo M, De Barrio M, Rubio M, Herrero T. Anaphylaxis due to caffeine. Allergy 2003;58(7):681-682. PubMed Fallbericht

  Gilt für Produkte: providing 200 mg or more caffeine, per day.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

  Von Health Canada zitierte Quellen (1)

  • Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.

  Gilt für Produkte: providing more than 400 mg caffeine, per day.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

  Von Health Canada zitierte Quellen (3)

  • IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
  • Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Übersichtsartikel
  • Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Übersichtsartikel

  Anwendungsbedingung: All products except those making a diuretic claim1.

  When using this product diuretic effect may occur.

  1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

  Monografie von Health Canada vom 19. Dezember 2025